Combining liposomes with cell-penetrating peptides increased delivery of a tau-blocking peptide into cells by 3-fold, with polyR and TAT sequences using different uptake mechanisms.
3-fold uptake increaseAdding cell-penetrating peptides to liposomes tripled the amount of tau-blocking peptide entering cells
What the researchers found
Liposome conjugation of CPP-containing RI-AG03 peptides increased cellular association three-fold compared to unconjugated liposomes. Both polyR (polyarginine) and TAT cell-penetrating sequences achieved this enhancement.
Inhibition of macropinocytosis reduced uptake of unconjugated and RI-AG03-polyR-linked liposomes, but had no effect on RI-AG03-TAT-conjugated liposome uptake, suggesting different internalization routes.
RI-AG03-polyR showed co-localization with macropinosomes and lysosomes. Importantly, RI-AG03-polyR detached from liposomes after cellular uptake, largely evading organellar entrapment. This is critical because drugs trapped in lysosomes are degraded and never reach their targets.
Why it matters
Tau aggregation is a hallmark of Alzheimer's disease. Tau aggregates form inside cells, so any tau-blocking drug must get inside cells to work. This study shows that liposome-CPP systems can deliver the tau inhibitor peptide into cells with three times higher efficiency, and the peptide avoids lysosomal degradation by detaching from the carrier once inside.
The numbers in context
- CPP-linked liposomes: 3x higher cellular uptake
- Both polyR and TAT sequences effective
- Macropinocytosis: involved in polyR but not TAT uptake
- RI-AG03-polyR: detached from liposomes inside cells
- Lysosomal escape: peptide largely avoided organellar entrapment
How the study worked
Researchers tested free RI-AG03, liposome-conjugated RI-AG03, and liposome-conjugated RI-AG03 with polyR or TAT CPP sequences. Cellular uptake was measured by fluorescence. Uptake mechanisms were probed with macropinocytosis inhibitors. Intracellular trafficking was visualized with co-localization microscopy. Peptide detachment from liposomes was confirmed inside cells.
Who was studied
In vitro cell culture study testing liposome-peptide delivery systems
What this study cannot tell us
In vitro cell culture study only. No animal model testing. The cells used may not represent the blood-brain barrier or neuronal cells that are the actual targets. Liposome-CPP systems face challenges in vivo including immune clearance, off-target uptake, and difficulty crossing the blood-brain barrier. Whether RI-AG03 actually inhibits tau aggregation inside cells was not tested in this study.
How to read the evidence
Rated preliminary: in vitro cell uptake study demonstrating delivery concept. No animal model or blood-brain barrier testing.
When this study was published
Published in 2024. Part of ongoing efforts to solve the drug delivery challenge in Alzheimer's therapeutics.
The bigger picture
Tau aggregation is a hallmark of Alzheimer's. Getting tau-blocking drugs inside neurons is a major challenge. This combination delivery approach shows promising results that could advance Alzheimer's drug development.
Questions still open
- Does the intracellular detachment from liposomes improve or reduce drug effectiveness?
- Can this system cross the blood-brain barrier?
Common questions
What is tau and why block its aggregation?
Why are cell-penetrating peptides needed?
Read the original research
Liposome nanoparticle conjugation and cell penetrating peptide sequences (CPPs) enhance the cellular delivery of the tau aggregation inhibitor RI-AG03.
Journal of cellular and molecular medicine, 28(11), e18477
Citation
Reich, Niklas; Parkin, Edward; Dawson, Neil. (2024). Liposome nanoparticle conjugation and cell penetrating peptide sequences (CPPs) enhance the cellular delivery of the tau aggregation inhibitor RI-AG03.. Journal of cellular and molecular medicine, 28(11), e18477. https://doi.org/10.1111/jcmm.18477